Ligand Reports Second Quarter 2019 Financial Results
Conference Call Begins at 9:00 a.m. Eastern Time Today SAN DIEGO–(BUSINESS WIRE)–Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results…
Pharmaceuticals, Biotechnology and Life Sciences
Conference Call Begins at 9:00 a.m. Eastern Time Today SAN DIEGO–(BUSINESS WIRE)–Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results…
NEW YORK–(BUSINESS WIRE)–#ChildhoodCancerAwareness—Massive Bio, Inc., a leader in precision medicine and artificial intelligence (AI) enabled patient centric clinical trial matching,…
Strong total revenue of $4.4 billion, increased 15% Y/Y driven by volume Company raises 2019 total revenue guidance; reaffirms 2020…
Acerus Pharmaceuticals to launch U.S. specialty sales force of at least 25 representatives Combined effort expected to optimize resources and…
Total product and royalty revenues of $510 million (+21% vs. Q2 2018) and Jakafi® (ruxolitinib) revenues of $410 million (+18%…
– Phase 2 study will evaluate efficacy of BLU-5937 and is expected to add to Phase 1 evidence showing little…
Sales of $599 million were flat as reported and grew 2% in constant currency Strong pharmaceutical growth, partially offset by…
Second-Quarter 2019 Worldwide Sales Were $11.8 Billion, an Increase of 12%; Sales Increased 15% Excluding Negative Impact from Foreign Exchange;…
Also Announces Leadership Succession Plan SCOTTSDALE, Ariz.–(BUSINESS WIRE)–Magellan Health, Inc. (NASDAQ: MGLN) today announced financial results for the second quarter…
STAMFORD, Conn.–(BUSINESS WIRE)–SpringWorks Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases…